Skip to main content

Advertisement

Analysis of microRNA from archived formalin-fixed paraffin-embedded specimens of amyotrophic lateral sclerosis

Acta Neuropathologica Communications volume 2, Article number: 173 (2014) Cite this article

Abstract

Background

MicroRNAs (miRNAs) are noncoding small RNAs that regulate gene expression. This study investigated whether formalin-fixed paraffin-embedded (FFPE) specimens from postmortem cases of neurodegenerative disorders would be suitable for miRNA profiling.

Results

Ten FFPE samples from 6 cases of amyotrophic lateral sclerosis (ALS) and 4 neurologically normal controls were selected for miRNA analysis on the basis of the following criteria for RNA quality: (i) a postmortem interval of less than 6 hours, (ii) a formalin fixation time of less than 4 weeks, (iii) an RNA yield per sample of more than 500 ng, and (iv) sufficient quality of the RNA agarose gel image. An overall RNA extraction success rate was 46.2%. For ALS, a total of 364 miRNAs were identified in the motor cortex, 91 being up-regulated and 233 down-regulated. Target genes were predicted using miRNA bioinformatics software, and the data applied to ontology analysis. This indicated that one of the miRNAs up-regulated in ALS (miR-338-3p) had already been identified in leukocytes, serum, cerebrospinal fluid and frozen spinal cord from ALS patients.

Conclusion

Although analysis was possible for just under half of the specimens examined, we were able to show that informative miRNA data can be derived from archived FFPE samples from postmortem cases of neurodegenerative disorders.

Introduction

MicroRNAs (miRNAs) are small, single-stranded, noncoding RNAs that regulate gene expression at the transcriptional and translational levels in both plants and animals [1]. A single miRNA may bind to as many as 200 target genes [2]. miRNAs are of great interest because they can regulate approximately 30% of human genes [3] and have a huge impact on a wide range of basic biological processes including developmental timing, cell death, cell proliferation, hematopoiesis and patterning of the nervous system [4]. The implications of miRNA network dysregulation have already been well demonstrated in the field of cancer research, suggesting that miRNAs may be good biomarkers for cancer diagnosis and prognosis [5]. The role of miRNAs has also been studied in neurodegenerative conditions such as Alzheimer’s disease [6]-[22], Parkinson’s disease [19],[23]-[27], Huntington’s disease [28]-[30], multiple system atrophy [31] and amyotrophic lateral sclerosis (ALS) [19],[32]-[36], postmortem frozen brain tissue having been employed in most cases [6]-[22],[26],[28],[30],[31]. Several investigators have also analyzed miRNAs from cerebrospinal fluid (CSF) [6],[34],[37], peripheral blood [33],[34],[37]-[39] and skeletal muscle [32],[35].

Although the yield, quality and integrity of RNA can be reduced through cross-linking with proteins, enzyme degradation as well as chemical degradation during the fixation process [40]-[44], the expression of miRNAs in formalin-fixed paraffin-embedded (FFPE) samples is known to be well correlated with that in fresh frozen samples [45]. Moreover, the expression of miRNAs is preserved after routine fixation in formalin (up to 5 days) and long-term storage in paraffin (up to 10 years) [45]. Therefore, FFPE samples have recently been used for studies of miRNA in cancer [46]-[51]. However, the stability and expression of miRNAs in FFPE specimens obtained postmortem and fixed for longer time periods (weeks or months) have not been investigated.

In the present study, we isolated RNAs from archived FFPE brain specimens of postmortem cases of ALS and neurologically normal controls. Although miRNA analysis was possible for only a minority of FFPE blocks, we were able to show that informative data can be derived from selected FFPE postmortem specimens of human brain.

Materials and methods

Subjects

To investigate the effect of postmortem interval, formalin fixation and storage period on the stability of RNA, we selected 10 samples (Table 1) that had been obtained at autopsy from 1 to 10 hours after death. The brains from which the specimens had been obtained had been immersed in 10% or 20% formalin or 10% phosphate-buffered formalin for 3–16 weeks. After fixation, the cerebrum had been cut into slices 10 mm thick in the coronal plane. Samples had then been removed from each slice and subjected to tissue processing (dehydration, clearing and impregnation) on an automated instrument (Tissue-Tek VIP 5 Jr., Sakura Finetek Japan, Tokyo, Japan) that employed seven steps of 100% ethanol, three steps of xylene, and four steps of paraffin, with 8 hours at each step. The instrument was operated under vacuum and heated to 37°C for the ethanol and xylene steps and 60°C for the paraffin steps. After tissue processing, each specimen had been embedded in paraffin, and the paraffin blocks had been stored for 10–86 months at room temperature protected from air and sunlight.

Table 1 Summary of fixed paraffin-embedded samples used for RNA isolation
Full size table

On the basis of the criteria reported by Osawa et al. [50], four criteria were adopted for establishing the suitability of the samples for RNA analysis: (i) a postmortem interval of less than 6 hours, (ii) a formalin fixation time of less than 4 weeks, (iii) a total RNA yield per sample of more than 500 ng, and (iv) sufficient quality of the RNA electrophoresis pattern.

We further evaluated an additional 16 samples (8 cases of ALS and 8 cases of normal controls) for which the postmortem interval had been less than 6 hours and the formalin fixation time had been less than 4 weeks. Thus, we evaluated a total of 26 samples. On this basis, 10 FFPE samples were selected for miRNA analysis, comprising 6 cases of sporadic ALS and 4 neurologically normal controls (Table 2). The FFPE specimens employed were from the motor cortex of patients with ALS and normal subjects. All the diagnoses had been confirmed by neuropathological examination using immunohistochemistry for TDP-43 and ubiquitin. This study was approved by the Institutional Ethics Committee of Hirosaki University Graduate School of Medicine, Japan.

Table 2 Characteristics of postmortem cases in microRNA study
Full size table

RNA extraction

Two 5-μm-thick sections were cut from each block and placed in sterile 1.5-mL centrifuge tubes ready for extraction. Tubes containing cut FFPE sections for RNA purification were stored at −80°C until use. Total RNA including small RNAs was extracted using an Arcturus® Paradise® PLUS FFPE RNA Isolation Kit (Life Technologies Corporation, Carlsbad, CA, USA) with the following modifications. Paraffin was removed by xylene treatment and the tissues were washed with ethanol twice to remove the xylene. The tissues were then treated with proteinase K at 37°C overnight, as proteinase K enables extraction of almost the same amount of RNA from FFPE specimens as from fresh frozen samples [52]. After centrifugation, the supernatant was processed with a silica-based spin column (Toray Industries Inc., Tokyo, Japan) in order to obtain purified total RNA. The degrees of RNA cross-linking and RNA degradation were analyzed by agarose gel electrophoresis using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). RNA yield was determined from the A 260/A 280 absorbance ratio using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA).

To assess the feasibility of analyzing RNA extracted from FFPE samples, we applied the selection criteria for RNA quality reported by Osawa et al. [50], as described above. The RNA electrophoresis pattern was found to be crucial for estimation of RNA quality. When the majority of RNAs were >4000 nucleotides (nt) in size due to cross-linking or when almost all of the RNAs were fragmented (e.g., <1000 nt), the RNA quality was considered unsuitable for miRNA analysis.

miRNA expression profiling

Extracted samples of total RNA that satisfied our criteria were labeled with Hy5 using a miRCURY LNA Array miR labeling kit (Exiqon, Vedbaek, Denmark). The labeled RNAs were then hybridized onto a 3D-Gene human miRNA oligo chip (Toray Industries Inc.). The annotation and oligonucleotide sequences of the probes conformed to the miRBase miRNA database Release 17v1.0.0 (http://www.mirbase.org/). After stringent washing, the fluorescent signals were scanned with a 3D-Gene Scanner (Toray Industries Inc.) and analyzed using 3D-Gene Extraction software (Toray Industries Inc.).

The raw data for each spot were normalized by subtraction of the mean intensity of the background signal determined from the signal intensities of all blank spots with 95% confidence intervals. Measurements for spots with signal intensities greater than 2 standard deviations (SD) of the background signal intensity were considered to be valid. The relative level of expression for a given miRNA was calculated by comparing the signal intensities of the valid spots throughout the microarray experiments. The normalized data were globally normalized per array, adjusting the median of the signal intensity to 25.

Any signal intensity level over 50 was considered to be significant. The signal was considered to be up-regulated when log2X was increased by 0.1 or more (≧log2X = +0.1) compared with the control signal level, and down-regulated when log2X was decreased by −0.1 or less (≦log2X = −0.1) compared with the control signal level.

miRNA targets and pathway analysis

Bioinformatics prediction of target genes and miRNA binding sites was performed using miRmap web-based open source software (http://mirmap.ezlab.org/) [53]. Canonical function and ontology analyses for candidate miRNA targets were performed using MetaCore Functional Analysis (ver.6.19, Thomson Reuter/GeneGo, http://lsresearch.thomsonreuters.com/) which is an integrated knowledge base and pathway analysis tool based on a proprietary manually curated database of human protein–protein, protein–DNA and protein compound interactions, and metabolic and signaling pathways, all supported by proprietary ontologies. Gene ontology enrichment analysis was also performed with Gene Ontology Consortium (GOC) web tool (http://geneontology.org/) to confirm standard GO term on the coincidences.

Immunohistochemistry

Since SOGA1 (suppressor of glucose by autophagy) [54] was identified as one of the candidate target genes of both up-regulated and down-regulated miRNAs, we evaluated the protein expression levels of autophagy-related genes such as AMBRA1 [55], Beclin 1 [56], ULK1 [57] and ULK2 [57] using immunohistochemistry. Serial 4-μm-thick FFPE sections from the motor cortex and spinal cord (7th cervical, 8th thoracic and 4th lumbar segments) of ALS patients (n = 13) were employed. We also examined neurologically normal individuals (normal control) (n = 6) and patients with various neurological diseases affecting the spinal anterior horn (diseased control) (n = 6). Three sections 40 μm apart were subjected to immunohistochemistry using the avidin-biotin-peroxidase complex method with a Vectastain ABC kit (Vector, Burlingame, CA, USA). The sections were subjected to heat retrieval using an autoclave for 10 min at 121°C in 10 mM citrate buffer (pH 6.0), and then immunostained with rabbit polyclonal antibodies against AMBRA1 (NOVUS USA, Littleton, CO, USA; 1:1000), Beclin 1 (NOVUS USA; 1:200), ULK1 (Thermo Scientific, Rockford, IL, USA; 1:100) and ULK2 (Thermo Scientific; 1:500). Diaminobenzidine was used as the chromogen, and the sections were counterstained with hematoxylin.

Semi-quantitative analysis

Since AMBRA1 immunoreactivity was decreased in the spinal anterior horn cells in ALS, we assessed the number of AMBRA1-immunoreactive neurons in the spinal anterior horn of control subjects and patients with ALS using a semi-quantitative rating scale, as reported previously [58]: −, unstained; +, weakly stained; ++, moderately or intensely stained. In each case, the numbers of neurons were counted in Rexed’s laminae VIII and IX of the lumbar spinal cord. Counting was performed at an original magnification of x200 using an eyepiece graticule and parallel sweeps of the microscope stage.

Statistical analysis

Calculations were performed using Statcel software (OMS Publishing, Tokorozawa, Japan). Repeated measures analysis of variance and Student’s or Welch’s t test were used to evaluate possible differences in staining intensity between normal controls, diseased controls and ALS. Values were expressed as mean ± standard error of the mean. Correlations at p < 0.05 were considered to be significant.

Results

Stability of RNA in postmortem samples

The RNA yield was not correlated with the period of storage of FFPE blocks. However, the RNA yield was influenced by the period of formalin fixation (Table 1), being significantly higher in samples that had been fixed for a short period (3–4 weeks; mean 2465 ng) than in those that have been fixed for a long period (8–16 weeks; mean 574 ng) (p < 0.05). The RNA yield did not appear to be affected by the type of fixative employed. Postmortem interval could be also relevant. Samples with higher RNA yield (samples 1, 2 and 8) were the cases in whom postmortem interval was within 4 hours. The rest with lower RNA yield (samples 3–7, 9 and 10) had a combination of longer postmortem interval (9–10 hours) and/or fixation (8–16 weeks). RNA integrity was checked by electrophoresis, and a representative RNA agarose gel image is shown in Figure 1. A band of 5000 nt corresponding to 28S ribosomal RNA was slightly shifted toward a higher molecular weight in all cases, indicating overfixation with formalin and the presence of chemical modifications of the RNA such as covalently linked residual amino acids [59]. A band of 2000 nt corresponding to 18S ribosomal RNA was seen in some cases (Figure 1), suggesting that the extracted RNA was of good quality. These bands were not only shifted, but also appeared more diffuse and less focused. The bands of 100–200 nt corresponded to degraded RNA, as reported previously [60]. On the basis of these initial analyses, we adopted four criteria to indicate that RNA would be of sufficient quality for analysis, based on Osawa et al. [50]: (i) a postmortem interval of less than 6 hours, (ii) a formalin fixation time of less than 4 weeks, (iii) a total RNA yield per sample of more than 500 ng, and (iv) a RNA electrophoresis pattern of good quality.

Figure 1
figure1

Effect of formalin fixation on RNA expression. Representative RNA agarose gel image showing a band of 2000 nt corresponding to 18S ribosomal RNA in lane 1. A faint band of 2000 nt is also seen in lanes 2 and 3. Lane 1, sample 2; lane 2, sample 1; lane 3, sample 8.

Full size image

We evaluated an additional 16 samples (8 cases of ALS and 8 cases of normal controls) for which the postmortem interval had been less than 6 hours and the formalin fixation time had been less than 4 weeks. The RNA yield was more than 500 ng for 12 of these samples, and the RNA agarose gel image was of sufficient quality in 4. As a result, we evaluated a total of 26 samples. The RNA yield was more than 500 ng in 20 of the 26 samples, and the RNA agarose gel image was of sufficient quality in 12. Thus, the success rate for analysis of RNA from FFPE samples of the human postmortem brain was 46.2% (12 of 26).

Based on the above step, 10 cases were selected for miRNA analysis; these included cases of sporadic ALS (n = 6) and neurologically normal controls (n = 4) (Table 2). In case 3, although the fixation time had been 8 weeks, it was included in the present analysis, because the RNA yield was more than 500 ng and the RNA agarose gel image was of sufficient quality.

miRNA analysis and candidate target genes in ALS

A total of 364 miRNAs were isolated from the motor cortex of patients with ALS. Forty miRNAs showed no change (−0.1 < log2X < +0.1), and 91 were up-regulated (log2X≧ + 0.1) and 233 were down-regulated (log2X≦ − 0.1) relative to the controls. Top 20 microRNAs up- or down-regulated in ALS are shown in Additional file 1: Table S1. miR-494 was found to be the most highly differentially up-regulated miRNA (+4.99-fold change), followed in order by miR-4257, miR-24-3p, miR-4299, and miR-1973 as the top 5 up-regulated miRNAs. On the other hand, miR-4740-5p (+0.19-fold change), miR-1290, miR-3619-3p, miR-1246, and miR-3180-3p were the top 5 down-regulated miRNAs.

Scatter plot of all 364 miRNAs comparing signal intensity versus log2 fold-change of ALS/control ratio is shown in Figure 2. We selected 6 up-regulated miRNAs (miR-494, miR-4257, miR-24-3p, miR-4299, miR-1973 and miR-4485) and 8 down-regulated miRNAs (miR-4740-5p, miR-1290, miR-3619-3p, miR-1246, miR-3180-3p, miR-4648, miR-4716-3p and miR-663) in ALS. The candidate target genes of the 6 up-regulated and 8 down-regulated miRNAs in ALS were identified using miRmap web-based open source software.

Figure 2
figure2

Scatter plot of all 364 miRNAs comparing signal intensity (X-axis) versus log 2 fold-change of amyotrophic lateral sclerosis (ALS)/control ratio (Y-axis). Based on the size of variation, 6 up-regulated and 8 down-regulated miRNAs were selected in ALS.

Full size image

Top 50 candidate target genes of each of the 6 up-regulated miRNAs in ALS were selected according to the miRmap score. Of the 300 target candidates identified for each of the 6 miRNAs, there was an overlap of 13 genes (Additional file 2: Table S2). These 13 genes have been reported to be involved in muscular cell proliferation (FOXK1 [61], MEF2D [62]), synaptic transmission (ITSN1 [63], RAB3B [64], SLC6A5 [65]), mitochondrial regulation (IBA57 [66], PPARGC1B [67]) and autophagy (MEF2D [68], SOGA1 [54]). These genes may be down-regulated by the 6 up-regulated miRNAs in affected brain regions of ALS. In addition, miR-24-3p showed the most matching frequency (7 overlapped in 50 targets) in up-regulated miRNAs.

Top 50 candidate target genes of each of the 8 down-regulated miRNAs in ALS were also selected. Of the 400 target candidates identified for each of the 8 miRNAs, there was an overlap of 34 genes (Additional file 3: Table S3). These 34 genes have been reported to play a role in neurogenesis (ONECUT2 [69], KDM5A [70], NAT8L [71], NFIX [72]), mitochondrial regulation (IBA57 [66]) and autophagy (PRLA [73], SNCB [74], SOGA1 [54]). In addition, miR-3180-3p showed the most matching frequency (14 overlapped in 50 targets) in down-regulated miRNAs.

It is important to note that 3 genes (IBA57, RAB3B and SOGA1) were identified as candidate target genes of both up-regulated and down-regulated miRNAs (Additional file 2: Table S2, Additional file 3: Table S3). IBA57 is known to be involved in the biosynthesis of mitochondrial [4Fe-4S] proteins [66]. Mutation of IBA57 causes severe myopathy and encephalopathy [66]. Rab3B is a synaptic vesicle protein that interacts with the Rab3-interacting molecule isoforms as effector proteins in a GTP-dependent manner [64]. The search for an inhibitor of autophagy in the adiponectin signaling pathway led to the discovery of the Suppressor of Glucose from Autophagy (SOGA) [54]. These findings suggest that mitochondrial regulation, synaptic transmission and autophagy may be affected in ALS. Considering that the expression level of up-regulated miRNAs is higher than that of down-regulated miRNAs (Figure 2), these 3 genes may be down-regulated in the motor cortex of ALS.

Gene ontology analysis of predicted target genes for disease-specific miRNAs

A total of 300 candidates for 6 up-regulated miRNAs and 400 candidates for 8 down-regulated miRNAs were nominated as targets for gene ontology enrichment analysis (biological process). Additional file 4: Table S4 (A, B) shows top 10 GO terms with MetaCore analysis and Additional file 4: Table S4 (C, D) shows top 10 GO terms with GOC analysis for standard GO terms. Two GO analyses suggested essentially similar biological process in up-regulated and down-regulated miRNA target genes.

The biological processes in ALS altered by these target genes were shown to be related to protein transport, synaptic vesicle-mediated transport, and localization for up-regulated miRNAs and nervous system development for down-regulated miRNAs, as shown in Additional file 4: Table S4.

Decrease of AMBRA1 immunoreactivity in ALS

Since SOGA1 was identified as one of the overlapped target genes predicted by 6 up-regulated and 8 down-regulated miRNAs, we hypothesized that alteration of autophagy is involved in the disease process of ALS. This may be supported by the findings that abnormal autophagy is involved in various neurodegenerative disorders, including ALS [75]-[79]. Therefore, we evaluated the protein expression levels of autophagy-related genes such as AMBRA1 [55], Beclin 1 [56], ULK1 [57] and ULK2 [57] by immunohistochemical examination of FFPE tissue.

In specimens from normal control subjects, anti-AMBRA1 antibody strongly immunolabeled the cytoplasm of upper and lower motor neurons in a diffuse granular pattern (Figure 3A-C), consistent with a previous study [80]. In ALS, AMBRA1 immunoreactivity was decreased in the majority of spinal anterior horn cells (Figure 3D-F), but not in the motor cortex (data not shown), in comparison with controls.

Figure 3
figure3

AMBRA1 immunoreactivity in the anterior horn of the lumbar cord in 3 normal controls (A-C) and 3 cases of ALS (D-F). AMBRA1 immunoreactivity is decreased in ALS relative to the controls. Bars = 100 μm.

Full size image

Semi-quantitative analysis of normal controls showed that 30.2% of anterior horn cells were moderately or intensely immunolabeled, 48.5% were weakly immunolabeled, and 21.3% were unstained (Figure 4). Similarly, in diseased controls, 20% of anterior horn cells were moderately or intensely immunolabeled and 33.7% were weakly immunolabeled (Figure 4). The differences in staining intensity between normal and diseased controls were not statistically significant. In ALS, a small proportion of anterior horn cells (5.2%) showed moderate or intense immunoreactivity, whereas the majority (83.5%) were unstained (Figure 4). The differences in staining intensity between normal control and ALS cases and between diseased control and ALS cases were significant.

Figure 4
figure4

AMBRA1 immunoreactivity in anterior horn cells from normal and diseased controls and patients with ALS. The proportions of neurons showing intense/moderate (++, black column), weak (+, gray column), or no immunostaining for AMBRA1 (−, white column) relative to the total number of neurons in the anterior horn are indicated.

Full size image

Immunoreactivity for Beclin 1, ULK1 and ULK2 was observed in the neuronal cytoplasm in normal controls. No significant difference was found in the staining intensity of these proteins between ALS and normal controls (data not shown).

Discussion

It has been reported that the formalin fixation and paraffin embedding process results in a marked reduction of detectable mRNA [81]. This process causes enzymatic degradation and chemical modification of RNA giving rise to cross-links with proteins and making RNA extraction difficult [52]. Therefore, a digestion step with proteinase K is required to eliminate cross-links and facilitate RNA extraction from FFPE samples [52]. The longer an RNA molecule is, the more likely cross-links will remain after proteinase K digestion, hence small RNA molecules will be easier to extract from FFPE samples and fragments larger than 200 nt will be harder to recover from FFPE samples. In addition, electrophoretic profiles of total RNA from frozen samples show three characteristic peaks: 40–80 nt, 90 nt and 150 nt, probably corresponding to tRNAs, rRNAs and snoRNAs, respectively. On the other hand, FFPE sample shows an accumulation of RNA fragments smaller than 200 nt [82]. These findings suggest that the amount of total RNA that can be extracted from a FFPE tissue sample is only a fraction of what can be extracted from its corresponding frozen tissue [81].

Although the number of subjects was small, we demonstrated for the first time that miRNAs extracted from FFPE samples of postmortem brain tissue from patients with neurodegenerative disorder (ALS) and neurologically normal controls were relatively well preserved; 12 of 26 samples (46.2%), for which the longest storage period was more than 7 years, provided RNA of sufficient quality. Thus, miRNAs appear to be relatively stable in FFPE samples, even those from postmortem specimens. It has been suggested that miRNAs are too small to be degraded [83]. However, this hypothesis has not been supported by any reported data. It is now known that active, mature miRNAs are processed and function via binding to Argonaute family proteins [84],[85]. These protein-miRNA complexes may protect the functional population of miRNA from degradation, especially during the process of formalin fixation and storage in paraffin [49]. Peiró-Chova et al. [82] have shown that the quantity of miRNAs from FFPE samples was higher than that obtained from frozen samples, since degradation of total RNA can produce fragments in the small RNA size range that could cause an overestimation in the proportion of its small sized fragments.

ALS is characterized by loss of upper and lower motor neurons. TDP-43 is now known to be a major component of ubiquitinated inclusions in ALS and frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U, since renamed FTLD-TDP) [86],[87]. Thus, these neurodegenerative disorders comprise a new disease concept: “TDP-43 proteinopathy”. Up- or down-regulated miRNAs in ALS in the present study and previously reported results are shown in Additional file 5: Table S5. Williams et al. [36] compared miRNA expression in skeletal muscle of normal and ALS model mice (G93A-SOD1 transgenic mice) and demonstrated that miR-206, a skeletal muscle-specific miRNA in humans and mice, delays disease progression in SOD1 transgenic mice. miR-206 is up-regulated in the skeletal muscle of ALS patients [32]. Shioya et al. [19] studied the miRNA expression profile in frozen samples of frontal cortex from three ALS patients using microarray analysis and found that miR-29a, miR-29b and miR-338-3p were up-regulated. Up-regulation of miR-29b has also been reported in skeletal muscle of ALS patients [35]. De Felice et al. [33] evaluated miRNA expression in leukocytes obtained from ALS patients and healthy controls and demonstrated that miR-338-3p was also up-regulated in ALS. Seven miRNAs (miR-451, miR-1275, miR-328, miR-638, miR-149, miR-665 and miR-583) were also down-regulated in ALS. Importantly, in our present study, three miRNAs (miR-29a, miR-29b and miR-338-3p) were also up-regulated and four miRNAs (miR-328, miR-451, miR-638 and miR-665) were down-regulated in FFPE samples of the motor cortex in ALS. Recently, De Felice et al. [34] further demonstrated that miR-338-3p was over-expressed in leukocytes, serum, CSF and frozen samples of spinal cord in patients with ALS, and that miR-338-3p expression in leukocytes was correlated with disease duration, suggesting that miR-338-3p may be a relevant clinical biomarker of ALS. It is likely that some miRNAs are systemically dysregulated in ALS and that miRNAs remain stable even in FFPE postmortem samples that have been stored for a long period.

We further demonstrated that AMBRA1 was significantly down-regulated in the lower motor neurons in ALS. This is in line with the results of our miRNA analysis that AMBRA1 is most possibly regulated by miR-24-3p according to miRmap prediction (the rank 1 in canonical miRNAs of miRmap score = 97.37) and that miR-24-3p is one of the highly up-regulated miRNAs in ALS (Additional file 1: Table S1). AMBRA1 is widely expressed in neurons in the normal mouse brain and is localized to the endoplasmic reticulum, perinuclear cisternae and outer mitochondrial membrane [80]. AMBRA1 interacts with Beclin 1, promoting its binding to lipid kinase Vps34, thus mediating autophagosome nucleation [55]. AMBRA1 is also known to be a Parkin-binding protein involved in mitophagy [88]. Abnormal autophagy is involved in various neurodegenerative disorders, including Alzheimer’s disease [75],[76], Parkinson’s disease [78], multiple system atrophy [79] and ALS [77]. A recent study has shown that administration of rapamycin, an MTOR-dependent autophagy activator, ameliorates neuronal degeneration in FTLD-TDP model mice [89]. By contrast, rapamycin also aggravates neuronal death in a mouse model of ALS [90]. Thus, induction or repression of autophagy should be taken into account when considering novel therapeutic approaches for TDP-43 proteinopathy.

Conclusion

In conclusion, we have utilized FFPE brain samples from postmortem cases of ALS and neurologically normal controls and found that miRNAs extracted from these samples were relatively well preserved. Although further studies with a larger sample size are necessary, it is likely that archived FFPE postmortem samples can be a valuable source for miRNA profiling in neurodegenerative disorders.

Additional files

References

  1. 1.

    Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281–297. 10.1016/S0092-8674(04)00045-5

  2. 2.

    Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6(4):259–269. 10.1038/nrc1840

  3. 3.

    Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120(1):15–20. 10.1016/j.cell.2004.12.035

  4. 4.

    Ambros V: The functions of animal microRNAs. Nature 2004, 431(7006):350–355. 10.1038/nature02871

  5. 5.

    Ma L, Weinberg RA: Micromanagers of malignancy: role of microRNAs in regulating metastasis. Trends Genet 2008, 24(9):448–456. 10.1016/j.tig.2008.06.004

  6. 6.

    Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, Kelnar K, Kemppainen J, Brown D, Chen C, Prinjha RK, Richardson JC, Saunders AM, Roses AD, Richards CA: Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimer’s Dis 2008, 14(1):27–41.

  7. 7.

    Cui JG, Li YY, Zhao Y, Bhattacharjee S, Lukiw WJ: Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-κB in stressed human astroglial cells and in Alzheimer disease. J Biol Chem 2010, 285(50):38951–38960. 10.1074/jbc.M110.178848

  8. 8.

    Faghihi MA, Zhang M, Huang J, Modarresi F, Van der Brug MP, Nalls MA, Cookson MR, St-Laurent G 3rd, Wahlestedt C: Evidence for natural antisense transcript-mediated inhibition of microRNA function. Genome Biol 2010, 11(5):R56. 10.1186/gb-2010-11-5-r56

  9. 9.

    Geekiyanage H, Chan C: MicroRNA-137/181c regulates serine palmitoyltransferase and in turn amyloid β, novel targets in sporadic Alzheimer’s disease. J Neurosci 2011, 31(41):14820–14830. 10.1523/JNEUROSCI.3883-11.2011

  10. 10.

    Götz J, Ittner LM, Fändrich M, Schonrock N: Is tau aggregation toxic or protective: a sensible question in the absence of sensitive methods? J Alzheimer’s Dis 2008, 14(4):423–429.

  11. 11.

    Hébert SS, Horré K, Nicolaï L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, Kauppinen S, Delacourte A, De Strooper B: Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased BACE1/β-secretase expression. Proc Natl Acad Sci U S A 2008, 105(17):6415–6420. 10.1073/pnas.0710263105

  12. 12.

    Hébert SS, Horré K, Nicolaï L, Bergmans B, Papadopoulou AS, Delacourte A, De Strooper B: MicroRNA regulation of Alzheimer’s amyloid precursor protein expression. Neurobiol Dis 2009, 33(3):422–428. 10.1016/j.nbd.2008.11.009

  13. 13.

    Hébert SS, Papadopoulou AS, Smith P, Galas MC, Planel E, Silahtaroglu AN, Sergeant N, Buée L, De Strooper B: Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Hum Mol Genet 2010, 19(20):3959–3969. 10.1093/hmg/ddq311

  14. 14.

    Lukiw WJ: Micro-RNA speciation in fetal, adult and Alzheimer’s disease hippocampus. Neuroreport 2007, 18(3):297–300. 10.1097/WNR.0b013e3280148e8b

  15. 15.

    Lukiw WJ, Zhao Y, Cui JG: An NF-κB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem 2008, 283(46):31315–31322. 10.1074/jbc.M805371200

  16. 16.

    Nunez-Iglesias J, Liu CC, Morgan TE, Finch CE, Zhou XJ: Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer’s disease cortex reveals altered miRNA regulation. PLoS One 2010, 5(2):e8898. 10.1371/journal.pone.0008898

  17. 17.

    Schratt G: microRNAs at the synapse. Nat Rev Neurosci 2009, 10(12):842–849. 10.1038/nrn2763

  18. 18.

    Sethi P, Lukiw WJ: Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer’s disease temporal lobe neocortex. Neurosci Lett 2009, 459(2):100–104. 10.1016/j.neulet.2009.04.052

  19. 19.

    Shioya M, Obayashi S, Tabunoki H, Arima K, Saito Y, Ishida T, Satoh J: Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3. Neuropathol Appl Neurobiol 2010, 36(4):320–330. 10.1111/j.1365-2990.2010.01076.x

  20. 20.

    Smith P, Al Hashimi A, Girard J, Delay C, Hébert SS: In vivo regulation of amyloid precursor protein neuronal splicing by microRNAs. J Neurochem 2011, 116(2):240–247. 10.1111/j.1471-4159.2010.07097.x

  21. 21.

    Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q, Rigoutsos I, Nelson PT: The expression of microRNA miR-107 decreases early in Alzheimer’s disease and may accelerate disease progression through regulation of β-site amyloid precursor protein-cleaving enzyme 1. J Neurosci 2008, 28(5):1213–1223. 10.1523/JNEUROSCI.5065-07.2008

  22. 22.

    Wang WX, Huang Q, Hu Y, Stromberg AJ, Nelson PT: Patterns of microRNA expression in normal and early Alzheimer’s disease human temporal cortex: white matter versus gray matter. Acta Neuropathol 2011, 121(2):193–205. 10.1007/s00401-010-0756-0

  23. 23.

    Doxakis E: Post-transcriptional regulation of α-synuclein expression by mir-7 and mir-153. J Biol Chem 2010, 285(17):12726–12734. 10.1074/jbc.M109.086827

  24. 24.

    Gehrke S, Imai Y, Sokol N, Lu B: Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 2010, 466(7306):637–641. 10.1038/nature09191

  25. 25.

    Junn E, Lee KW, Jeong BS, Chan TW, Im JY, Mouradian MM: Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci U S A 2009, 106(31):13052–13057. 10.1073/pnas.0906277106

  26. 26.

    Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV, Murchison E, Hannon G, Abeliovich A: A microRNA feedback circuit in midbrain dopamine neurons. Science 2007, 317(5842):1220–1224. 10.1126/science.1140481

  27. 27.

    Wang G, van der Walt JM, Mayhew G, Li YJ, Züchner S, Scott WK, Martin ER, Vance JM: Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of α-synuclein. Am J Hum Genet 2008, 82(2):283–289. 10.1016/j.ajhg.2007.09.021

  28. 28.

    Johnson R, Zuccato C, Belyaev ND, Guest DJ, Cattaneo E, Buckley NJ: A microRNA-based gene dysregulation pathway in Huntington’s disease. Neurobiol Dis 2008, 29(3):438–445. 10.1016/j.nbd.2007.11.001

  29. 29.

    Lee ST, Chu K, Im WS, Yoon HJ, Im JY, Park JE, Park KH, Jung KH, Lee SK, Kim M, Roh JK: Altered microRNA regulation in Huntington’s disease models. Exp Neurol 2011, 227(1):172–179. 10.1016/j.expneurol.2010.10.012

  30. 30.

    Packer AN, Xing Y, Harper SQ, Jones L, Davidson BL: The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington’s disease. J Neurosci 2008, 28(53):14341–14346. 10.1523/JNEUROSCI.2390-08.2008

  31. 31.

    Ubhi K, Rockenstein E, Kragh C, Inglis C, Spencer B, Michael S, Mante M, Adame A, Galasko D, Masliah E: Widespread microRNA dysregulation in multiple system atrophy - disease-related alteration in miR-96. Eur J Neurosci 2014, 39(6):1026–1041. 10.1111/ejn.12444

  32. 32.

    Bruneteau G, Simonet T, Bauché S, Mandjee N, Malfatti E, Girard E, Tanguy ML, Behin A, Khiami F, Sariali E, Hell-Remy C, Salachas F, Pradat PF, Fournier E, Lacomblez L, Koenig J, Romero NB, Fontaine B, Meininger V, Schaeffer L, Hantaï D: Muscle histone deacetylase 4 upregulation in amyotrophic lateral sclerosis: potential role in reinnervation ability and disease progression. Brain 2013, 136(Pt 8):2359–2368. 10.1093/brain/awt164

  33. 33.

    De Felice B, Guida M, Guida M, Coppola C, De Mieri G, Cotrufo R: A miRNA signature in leukocytes from sporadic amyotrophic lateral sclerosis. Gene 2012, 508(1):35–40. 10.1016/j.gene.2012.07.058

  34. 34.

    De Felice B, Annunziata A, Fiorentino G, Borra M, Biffali E, Coppola C, Cotrufo R, Brettschneider J, Giordana ML, Dalmay T, Wheeler G, D’Alessandro R (2014) miR-338–3p is over-expressed in blood, CFS, serum and spinal cord from sporadic amyotrophic lateral sclerosis patients. Neurogenetics: Epub ahead of print

  35. 35.

    Russell AP, Wada S, Vergani L, Hock MB, Lamon S, Léger B, Ushida T, Cartoni R, Wadley GD, Hespel P, Kralli A, Soraru G, Angelini C, Akimoto T: Disruption of skeletal muscle mitochondrial network genes and miRNAs in amyotrophic lateral sclerosis. Neurobiol Dis 2012, 49C: 107–117.

  36. 36.

    Williams AH, Valdez G, Moresi V, Qi X, McAnally J, Elliott JL, Bassel-Duby R, Sanes JR, Olson EN: MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 2009, 326(5959):1549–1554. 10.1126/science.1181046

  37. 37.

    Freischmidt A, Müller K, Ludolph AC, Weishaupt JH: Systemic dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis. Acta Neuropathol Commun 2013, 1(1):42. 10.1186/2051-5960-1-42

  38. 38.

    Margis R, Margis R, Rieder CR: Identification of blood microRNAs associated to Parkinson’s disease. J Biotechnol 2011, 152(3):96–101. 10.1016/j.jbiotec.2011.01.023

  39. 39.

    Schipper HM, Maes OC, Chertkow HM, Wang E: MicroRNA expression in Alzheimer blood mononuclear cells. Gene Regul Syst Bio 2007, 1: 263–274.

  40. 40.

    Doleshal M, Magotra AA, Choudhury B, Cannon BD, Labourier E, Szafranska AE: Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues. J Mol Diagn 2008, 10(3):203–211. 10.2353/jmoldx.2008.070153

  41. 41.

    Glud M, Klausen M, Gniadecki R, Rossing M, Hastrup N, Nielsen FC, Drzewiecki KT: MicroRNA expression in melanocytic nevi: the usefulness of formalin-fixed, paraffin-embedded material for miRNA microarray profiling. J Invest Dermatol 2009, 129(5):1219–1224. 10.1038/jid.2008.347

  42. 42.

    Lewis F, Maughan NJ, Smith V, Hillan K, Quirke P: Unlocking the archive–gene expression in paraffin-embedded tissue. J Pathol 2001, 195(1):66–71. 10.1002/1096-9896(200109)195:1<66::AID-PATH921>3.0.CO;2-F

  43. 43.

    Liu A, Tetzlaff MT, Vanbelle P, Elder D, Feldman M, Tobias JW, Sepulveda AR, Xu X: MicroRNA expression profiling outperforms mRNA expression profiling in formalin-fixed paraffin-embedded tissues. Int J Clin Exp Pathol 2009, 2(6):519–527.

  44. 44.

    Szafranska AE, Davison TS, Shingara J, Doleshal M, Riggenbach JA, Morrison CD, Jewell S, Labourier E: Accurate molecular characterization of formalin-fixed, paraffin-embedded tissues by microRNA expression profiling. J Mol Diagn 2008, 10(5):415–423. 10.2353/jmoldx.2008.080018

  45. 45.

    Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, Ju J: Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007, 13(10):1668–1674. 10.1261/rna.642907

  46. 46.

    Bing Z, Master SR, Tobias JW, Baldwin DA, Xu XW, Tomaszewski JE: MicroRNA expression profiles of seminoma from paraffin-embedded formalin-fixed tissue. Virchows Arch 2012, 461(6):663–668. 10.1007/s00428-012-1325-9

  47. 47.

    Chen L, Li Y, Fu Y, Peng J, Mo MH, Stamatakos M, Teal CB, Brem RF, Stojadinovic A, Grinkemeyer M, McCaffrey TA, Man YG, Fu SW: Role of deregulated microRNAs in breast cancer progression using FFPE tissue. PLoS One 2013, 8(1):e54213. 10.1371/journal.pone.0054213

  48. 48.

    Ibusuki M, Fu P, Yamamoto S, Fujiwara S, Yamamoto Y, Honda Y, Iyama K, Iwase H: Establishment of a standardized gene-expression analysis system using formalin-fixed, paraffin-embedded, breast cancer specimens. Breast Cancer 2013, 20(2):159–166. 10.1007/s12282-011-0318-x

  49. 49.

    Lee TS, Jeon HW, Kim YB, Kim YA, Kim MA, Kang SB: Aberrant microRNA expression in endometrial carcinoma using formalin-fixed paraffin-embedded (FFPE) tissues. PLoS One 2013, 8(12):e81421. 10.1371/journal.pone.0081421

  50. 50.

    Osawa S, Shimada Y, Sekine S, Okumura T, Nagata T, Fukuoka J, Tsukada K: MicroRNA profiling of gastric cancer patients from formalin-fixed paraffin-embedded samples. Oncol Lett 2011, 2(4):613–619.

  51. 51.

    Penland SK, Keku TO, Torrice C, He X, Krishnamurthy J, Hoadley KA, Woosley JT, Thomas NE, Perou CM, Sandler RS, Sharpless NE: RNA expression analysis of formalin-fixed paraffin-embedded tumors. Lab Invest 2007, 87(4):383–391.

  52. 52.

    Masuda N, Ohnishi T, Kawamoto S, Monden M, Okubo K: Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. Nucleic Acids Res 1999, 27(22):4436–4443. 10.1093/nar/27.22.4436

  53. 53.

    Vejnar CE, Zdobnov EM: miRmap: Comprehensive prediction of microRNA target repression strength. Nucleic Acids Res 2012, 40(22):11673–11683. 10.1093/nar/gks901

  54. 54.

    Cowherd RB, Asmar MM, Alderman JM, Alderman EA, Garland AL, Busby WH, Bodnar WM, Rusyn I, Medoff BD, Tisch R, Mayer-Davis E, Swenberg JA, Zeisel SH, Combs TP: Adiponectin lowers glucose production by increasing SOGA. Am J Pathol 2010, 177(4):1936–1945. 10.2353/ajpath.2010.100363

  55. 55.

    Fimia GM, Stoykova A, Romagnoli A, Giunta L, Di Bartolomeo S, Nardacci R, Corazzari M, Fuoco C, Ucar A, Schwartz P, Gruss P, Piacentini M, Chowdhury K, Cecconi F: Ambra1 regulates autophagy and development of the nervous system. Nature 2007, 447(7148):1121–1125.

  56. 56.

    Zhong Y, Wang QJ, Li X, Yan Y, Backer JM, Chait BT, Heintz N, Yue Z: Distinct regulation of autophagic activity by Atg14L and Rubicon associated with Beclin 1-phosphatidylinositol-3-kinase complex. Nat Cell Biol 2009, 11(4):468–476. 10.1038/ncb1854

  57. 57.

    Chan EY, Longatti A, McKnight NC, Tooze SA: Kinase-inactivated ULK proteins inhibit autophagy via their conserved C-terminal domains using an Atg13-independent mechanism. Mol Cell Biol 2009, 29(1):157–171. 10.1128/MCB.01082-08

  58. 58.

    Mori F, Tanji K, Miki Y, Wakabayashi K: Decreased cystatin C immunoreactivity in spinal motor neurons and astrocytes in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2009, 68(11):1200–1206. 10.1097/NEN.0b013e3181bdcdce

  59. 59.

    Groelz D, Sobin L, Branton P, Compton C, Wyrich R, Rainen L: Non-formalin fixative versus formalin-fixed tissue: a comparison of histology and RNA quality. Exp Mol Pathol 2013, 94(1):188–194. 10.1016/j.yexmp.2012.07.002

  60. 60.

    von Ahlfen S, Missel A, Bendrat K, Schlumpberger M: Determinants of RNA quality from FFPE samples. PLoS One 2007, 2(12):e1261. 10.1371/journal.pone.0001261

  61. 61.

    Shi X, Wallis AM, Gerard RD, Voelker KA, Grange RW, DePinho RA, Garry MG, Garry DJ: Foxk1 promotes cell proliferation and represses myogenic differentiation by regulating Foxo4 and Mef2. J Cell Sci 2012, 125(Pt 22):5329–5337. 10.1242/jcs.105239

  62. 62.

    Liu N, Nelson BR, Bezprozvannaya S, Shelton JM, Richardson JA, Bassel-Duby R, Olson EN: Requirement of MEF2A, C, and D for skeletal muscle regeneration. Proc Natl Acad Sci U S A 2014, 111(11):4109–4114. 10.1073/pnas.1401732111

  63. 63.

    Humphries AC, Donnelly SK, Way M: Cdc42 and the Rho GEF intersectin-1 collaborate with Nck to promote N-WASPdependent actin polymerisation. J Cell Sci 2014, 127(Pt 3):673–685. 10.1242/jcs.141366

  64. 64.

    Tsetsenis T, Younts TJ, Chiu CQ, Kaeser PS, Castillo PE, Südhof TC: Rab3B protein is required for long-term depression of hippocampal inhibitory synapses and for normal reversal learning. Proc Natl Acad Sci U S A 2011, 108(34):14300–14305. 10.1073/pnas.1112237108

  65. 65.

    Carta E, Chung SK, James VM, Robinson A, Gill JL, Remy N, Vanbellinghen JF, Drew CJ, Cagdas S, Cameron D, Cowan FM, Del Toro M, Graham GE, Manzur AY, Masri A, Rivera S, Scalais E, Shiang R, Sinclair K, Stuart CA, Tijssen MA, Wise G, Zuberi SM, Harvey K, Pearce BR, Topf M, Thomas RH, Supplisson S, Rees MI, Harvey RJ: Mutations in the GlyT2 gene (SLC6A5) are a second major cause of startle disease. J Biol Chem 2012, 287(34):28975–28985. 10.1074/jbc.M112.372094

  66. 66.

    Ajit Bolar N, Vanlander AV, Wilbrecht C, Van der Aa N, Smet J, De Paepe B, Vandeweyer G, Kooy F, Eyskens F, De Latter E, Delanghe G, Govaert P, Leroy JG, Loeys B, Lill R, Van Laer L, Van Coster R: Mutation of the iron-sulfur cluster assembly gene IBA57 causes severe myopathy and encephalopathy. Hum Mol Genet 2013, 22(13):2590–2602. 10.1093/hmg/ddt107

  67. 67.

    Rowe GC, Jang C, Patten IS, Arany Z: PGC-1β regulates angiogenesis in skeletal muscle. Am J Physiol Endocrinol Metab 2011, 301(1):E155-E163. 10.1152/ajpendo.00681.2010

  68. 68.

    Yang Q, She H, Gearing M, Colla E, Lee M, Shacka JJ, Mao Z: Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy. Science 2009, 323(5910):124–127. 10.1126/science.1166088

  69. 69.

    Francius C, Clotman F: Dynamic expression of the Onecut transcription factors HNF-6, OC-2 and OC-3 during spinal motor neuron development. Neuroscience 2010, 165(1):116–129. 10.1016/j.neuroscience.2009.09.076

  70. 70.

    Shen E, Shulha H, Weng Z, Akbarian S (2004) Regulation of histone H3K4 methylation in brain development and disease. Philos Trans R Soc Lond B Biol Sci 369(1652). doi:10.1098/rstb.2013.0514

  71. 71.

    Toriumi K, Ikami M, Kondo M, Mouri A, Koseki T, Ibi D, Furukawa-Hibi Y, Nagai T, Mamiya T, Nitta A, Yamada K, Nabeshima T: SHATI/NAT8L regulates neurite outgrowth via microtubule stabilization. J Neurosci Res 2013, 91(12):1525–1532. 10.1002/jnr.23273

  72. 72.

    Wilczynska KM, Singh SK, Adams B, Bryan L, Rao RR, Valerie K, Wright S, Griswold-Prenner I, Kordula T: Nuclear factor I isoforms regulate gene expression during the differentiation of human neural progenitors to astrocytes. Stem Cells 2009, 27(5):1173–1181. 10.1002/stem.35

  73. 73.

    Wei J, Fujita M, Nakai M, Waragai M, Watabe K, Akatsu H, Rockenstein E, Masliah E, Hashimoto M: Enhanced lysosomal pathology caused by β-synuclein mutants linked to dementia with Lewy bodies. J Biol Chem 2007, 282(39):28904–28914. 10.1074/jbc.M703711200

  74. 74.

    Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK: Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep 2014, 7(2):488–500. 10.1016/j.celrep.2014.03.009

  75. 75.

    Choi AM, Ryter SW, Levine B: Autophagy in human health and disease. N Engl J Med 2013, 368(7):651–662. 10.1056/NEJMra1205406

  76. 76.

    Nixon RA, Yang DS: Autophagy failure in Alzheimer’s disease–locating the primary defect. Neurobiol Dis 2011, 43(1):38–45. 10.1016/j.nbd.2011.01.021

  77. 77.

    Sasaki S: Autophagy in spinal cord motor neurons in sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2011, 70(5):349–359. 10.1097/NEN.0b013e3182160690

  78. 78.

    Tanji K, Mori F, Kakita A, Takahashi H, Wakabayashi K: Alteration of autophagosomal proteins (LC3, GABARAP and GATE-16) in Lewy body disease. Neurobiol Dis 2011, 43(3):690–697. 10.1016/j.nbd.2011.05.022

  79. 79.

    Tanji K, Odagiri S, Maruyama A, Mori F, Kakita A, Takahashi H, Wakabayashi K: Alteration of autophagosomal proteins in multiple system atrophy. Neurobiol Dis 2012, 49C: 190–198.

  80. 80.

    Sepe S, Nardacci R, Fanelli F, Rosso P, Bernardi C, Cecconi F, Mastroberardino PG, Piacentini M, Moreno S: Expression of Ambra1 in mouse brain during physiological and Alzheimer type aging. Neurobiol Aging 2014, 35(1):96–108. 10.1016/j.neurobiolaging.2013.07.001

  81. 81.

    Abrahamsen HN, Steiniche T, Nexo E, Hamilton-Dutoit SJ, Sorensen BS: Towards quantitative mRNA analysis in paraffin-embedded tissues using real-time reverse transcriptase-polymerase chain reaction: a methodological study on lymph nodes from melanoma patients. J Mol Diagn 2003, 5(1):34–41. 10.1016/S1525-1578(10)60449-7

  82. 82.

    Peiró-Chova L, Peña-Chilet M, López-Guerrero JA, García-Giménez JL, Alonso-Yuste E, Burgues O, Lluch A, Ferrer-Lozano J, Ribas G: High stability of microRNAs in tissue samples of compromised quality. Virchows Arch 2013, 463(6):765–774. 10.1007/s00428-013-1485-2

  83. 83.

    Hui AB, Shi W, Boutros PC, Miller N, Pintilie M, Fyles T, McCready D, Wong D, Gerster K, Waldron L, Jurisica I, Penn LZ, Liu FF: Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest 2009, 89(5):597–606. 10.1038/labinvest.2009.12

  84. 84.

    Hutvagner G, Simard MJ: Argonaute proteins: key players in RNA silencing. Nat Rev Mol Cell Biol 2008, 9(1):22–32. 10.1038/nrm2321

  85. 85.

    Mourelatos Z, Dostie J, Paushkin S, Sharma A, Charroux B, Abel L, Rappsilber J, Mann M, Dreyfuss G: miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev 2002, 16(6):720–728. 10.1101/gad.974702

  86. 86.

    Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T: TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006, 351(3):602–611. 10.1016/j.bbrc.2006.10.093

  87. 87.

    Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM: Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314(5796):130–133. 10.1126/science.1134108

  88. 88.

    Van Humbeeck C, Cornelissen T, Hofkens H, Mandemakers W, Gevaert K, De Strooper B, Vandenberghe W: Parkin interacts with Ambra1 to induce mitophagy. J Neurosci 2011, 31(28):10249–10261. 10.1523/JNEUROSCI.1917-11.2011

  89. 89.

    Wang IF, Guo BS, Liu YC, Wu CC, Yang CH, Tsai KJ, Shen CK: Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc Natl Acad Sci U S A 2012, 109(37):15024–15029. 10.1073/pnas.1206362109

  90. 90.

    Zhang X, Li L, Chen S, Yang D, Wang Y, Zhang X, Wang Z, Le W: Rapamycin treatment augments motor neuron degeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis. Autophagy 2011, 7(4):412–425. 10.4161/auto.7.4.14541

Download references

Acknowledgements

The authors wish to express their gratitude to M. Nakata, A. Ono and Y. Hama for technical assistance.

Funding

This work was supported by JSPS KAKENHI Grant Number 26430049 (F.M.) and 24300131 (K.W.), a Grant from Japan Science and Technology Program (AS2314204F) (H.S., K.W.), a Grant for Hirosaki University Institutional Research (K.W.), the Collaborative Research Project (2014–2508) of the Brain Research Institute, Niigata University (F.M.), Grants-in-Aid for Research on rare and intractable diseases, the Research Committee on Establishment of Novel Treatments for Amyotrophic Lateral Sclerosis (H.S.), the Research Committee for Ataxic Disease (H.S., K.W.) and the Research Committee of CNS Degenerative Diseases (H.S.) from the Ministry of Health, Labour and Welfare, Japan, and an Intramural Research Grant (24–5) for Neurological and Psychiatric Disorders of NCNP (K.W.).

Author information

Affiliations

  1. Department of Neuropathology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, 036-8562, Japan
    • Koichi Wakabayashi
    •  & Fumiaki Mori
  2. Department of Pathological Neuroscience, Center for Bioresource-based Researches, Brain Research Institute, University of Niigata, Niigata, Japan
    • Akiyoshi Kakita
  3. Department of Pathology, Brain Research Institute, University of Niigata, Niigata, Japan
    • Hitoshi Takahashi
  4. Department of Neurology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    • Jun Utsumi
    •  & Hidenao Sasaki
Authors
  1. Search for Koichi Wakabayashi in:
  2. Search for Fumiaki Mori in:
  3. Search for Akiyoshi Kakita in:
  4. Search for Hitoshi Takahashi in:
  5. Search for Jun Utsumi in:
  6. Search for Hidenao Sasaki in:

Corresponding author

Correspondence to Koichi Wakabayashi.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

JU, HS and KW managed the study and were principally responsible for writing. FM, AK, HT and KW performed the neuropathological observation and evaluation. JU performed bioinformatics analysis. HS and KW supervised whole process of the study. All authors read and approved the final manuscript.

Electronic supplementary material

Authors’ original submitted files for images

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wakabayashi, K., Mori, F., Kakita, A. et al. Analysis of microRNA from archived formalin-fixed paraffin-embedded specimens of amyotrophic lateral sclerosis. acta neuropathol commun 2, 173 (2014) doi:10.1186/s40478-014-0173-z

Download citation

Keywords

  • AMBRA1
  • Amyotrophic lateral sclerosis
  • Autophagy
  • Bioinformatics
  • Formalin-fixed paraffin-embedded specimen
  • MicroRNA

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us